https://doi.org/10.4081/scenario.2014.102

Sindrome da Ipertermia Maligna: una revisione bibliografica

V. 31 N. 4 (2014): Scenario 4 2014
Ricevuto: 19 gennaio 2018
Accettato: 19 gennaio 2018
Pubblicato: 19 gennaio 2018
Abstract Views: 247
PDF: 486
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Autori

Introduzione: la sindrome da Ipertermia Maligna o Malignant Hyperthermia (MH) è una rara e gravissima complicanza dell’anestesia generale, che si presenta in soggetti geneticamente predisposti in seguito all’esposizione a fattori scatenanti (gas alogenati e succinilcolina cloruro). È un’emergenza medica che non presenta un quadro clinico di chiara identificazione. Tutti gli infermieri, specie quelli d’anestesia, dovrebbero essere formati per essere pronti a gestirla.

Dimensions

Altmetric

PlumX Metrics

Downloads

I dati di download non sono ancora disponibili.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
DENbOROugH MA, LOvELL RRH. Anaesthetic deaths in a family. Lancet 2(45), 1960.
TARuSCIO D. Le malattie rare. In: Malattie rare in età pediatrica. Istituto Superiore Sanità . [Online] 2014. Available from www.iss.it/cnmr cited
March 16.
ROSEMbERg H, DAvIS M, JAMES D, POLLOCk N, STOwELL K. Malignant Hyperthermia, Orphanet J Rare Dis. 2007; Apr; 24; 2:21.
ACCORSI A, bRANCADORO v, CARSANA A, COZZOLINO S, DI MARTINO A, FORTuNATO G et al. [Raccomandazioni in tema di Ipertermia Maligna. Gruppo di stu-
dio SIAARTI per la sicurezza in Anestesia e Terapia Intensiva]. Minerva Anest 1997 Sep;63(9):279-85.
LI g, bRADy JE, ROSENbERg H, SuN LS. Excess comorbidities associated with malignant hyperthermia diagnosis in pediatric hospital discharge re-
cords. Paediatr Anaesth. 2011 Sept; 21(9): 958-63.
DuNN D. Malignant hyperthermia. AORN J. 1997 Apr; 65(4): 728-31.
gROuP EMH. A protocol for the investigation of malignant hyperpirexia (MH). Br J Anaesth. 2010; 105(4): 417-20.
ANDERSON-POMPA k, FOSTER A, PARkER L, wILkS L, CHEEk D, MILL T, et al. Genetics and susceptibility to malignant hyperthermia. Crit Care Nurse. 2008
Dec; 6(28): 32-6.
JAMES D, POLLOCk N, ROSEMbERg H, DAvIS M. Malignant hyperthermia. Orphanet Journal of Rare Diseases. 2007; 21(2). HOPkINS P. Malignant hyper- thermia: pharmacology of triggering. British Journal of Anaesthesia. 2011 May 30; 107(1): 48-56.
LITMAN R, ROSEMbERg H. Malignant hyperthermia: update on susceptibility testing. JAMA. 2005 Jun 15; 293(23): 2918-24.
LARACH bg, bRANDOM bw, ALLEN gC, gRONERT gA, LEHAM EB. Cardiac arrests and deaths associated with malignant hyperthermia in North America from 1987 to 2006: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the Uni-
ted States. Anesthesiology. 2008 Apr; 108(4): 603-11.
kIM T, NEMERguT M. Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and pre-
sent practice. Anesthesiology. 2011 Jan; 114(1): 205-12.
CHANg C, SCHER R. Malignantr hyperthermia and the otolaryngologist. Ear Nose Throat J. 2003 Jun; 82(6): 433-6.
NATHAN M. Malignant hyperthermia: perioperative considerations. Semin Perioper Nurs. 1993 Jan; 2(1): 38-44.
MIRANDA A, DONOvAN L, SCHuSTER L, gERbER D. Malignant hyperthermia. Am J Crit Care. 1997 Sep; 6(5): 368-74.
wOLCOTT k, MCDONNELL A. Malignant hyperthermia: nursing implications. Crit Care Nurse. 1990 Mar; 10(3): 78-85.
MARTIN S, vANE E. Malignant hyperthermia: a case study. Semin Perioper Nurs. 2000 Jan; 9(1): 27-36.
ROSEMbERg H, RuEFFERT H. Clinical utility gene card for malignant hyperthermia. European Journal of Human Genetics. 2011 Jan 19 doi:
1038/ejhg.2010.248; [published online 19 January 2011].
wAPPLER F. Anesthesia for patients with a history of malignant hyperthermia. Curr Opin Anaesthesiol. 2010 Jun; 23(3): 417-22.
wAPPLER F. Preparation of modern anesthesia workstations for malignant hyperthermia-suceptible patients: when are they really clean? Anes-
thesiology. 2011 Aug; 2(115): 434-5.
kugLER y, RuSSELL w. Speeding dantrolene preparation for treating malignant hyperthermia. Anaesth Intensive Care. 2011 Jan; 39(1): 84-8.
bRANDOM b, LARACH M, CHEN M, yOuNg M. Complications associated with the administration of dantrolene 1987 to 2006: a report from the North
American Malignant Hyperthermia Registry of the United States. Anesth Analg. 2011 May; 5(112): 1115-23.
PODRANSkI T, bOuILLON T, SCHuMACHER P, TAguCHI A, SESSLER D, kuRZ A. Compartmental pharmacokinetics of dantrolene in adults: do malignant hyper-
thermia association dosing guidelines work? Anesth Analg. 2005 Dec; 101(6): 1695-9.
INADA H, JINNO S, kOHASE H, FukAyAMA H, uMINO M. Postoperative hyperthermia of unknown origin treated with dantrolene sodium. Anesth Prog.
; 52(1): 21-3.
bAkER k, LANDRISCINA D, kARTCHNER H, MIRkES D. The Icarus effect: the in uence of diluent warming on dantrolene sodium mixing time. AANA J. 2007
Apr; 75(2): 101-6.
HALASZyNSkI T, JuDA R, SILvERMAN D. Optimizing postoperative outcomes with ef cient preoperative assessment and management. Crit Care Med.
Apr; 32(4): 76-86.
bLOCk FJ. Malignant hyperthermia and charcoal absorbent: too hot to handle. Anesth Analg. 2011 Jun; 6(112): 1270-1.
HOTCHkISSM,MENDOZAS.Updatefornurseanesthetists.Part6.Fullbodypatientsimulationtechnology:gainingexperienceusingamalignant
hyperthermia model. AANA J. 2001 Feb; 69(1): 59-65.

Agenzie di supporto

Aniarti ha scelto di applicare la Licenza Creative Commons Attribuzione Non Commerciale 4.0 Internazionale (CC BY-NC 4.0) a tutti i manoscritti da pubblicare.